12 webinars results for

Since the approval of the gene therapy product Luxtura® using AAV as a vector in 2017, more and more

Cell and gene therapies (CGT) are transforming disease treatment, with CAR-T therapies facing challenges

Whereas, viral vectors can serve as vehicles to deliver therapeutic genes to treat monogenic disorders

Director of Platform R&D Department, manages the platform R&D department to develop antibody, protein, and gene

lead CGT CDMO platform for the development and manufacturing of plasmid and viral vectors for cell & gene

expanded its plasmid DNA and viral vector production capacity with the opening of its flagship Cell and Gene

platform process R&D department to develop process R&D platforms based on antibodies, proteins, and gene

Pre-clinical through clinical to commercial supply, ProBio is marching forward to support more cell and gene

screening for both IgG and VHH antibody, and HTP cell-to-antibody conversion system without sequencing or gene

products are one of the most common non-viral vectors, frequently used in both in vivo and ex vivo gene